@article{08d8dd060de5413f96838b2ca0c69d66,
title = "Ocular surface disease is common in moderate-to-severe atopic dermatitis patients",
keywords = "atopic dermatitis, goblet cell, ocular surface disease",
author = "Achten, {Roselie E} and Bakker, {Daphne S} and {van Luijk}, {Chantal M} and {van der Wal}, {M Marlot} and {de Graaf}, Marlies and {van Wijk}, Femke and Zuithoff, {Nicolaas P A} and {van der Rijst}, {Lisa P} and Boesjes, {Celeste M} and Thijs, {Judith L} and {de Boer}, {Joke H} and {de Bruin-Weller}, {Marjolein S}",
note = "Funding Information: Roselie E. Achten has nothing to disclose. Daphne S. Bakker is a speaker for Sanofi Genzyme and LEO Pharma. Chantal M. van Luijk is a speaker for Sanofi Genzyme and Santen. Marlot van der Wal has nothing to disclose. Marlies de Graaf is a principal investigator and advisory board member and/or speaker for Sanofi Genzyme and Regeneron Pharmaceuticals and LEO Pharma. Femke van Wijk is a speaker and/or consultant for Janssen, Johnson & Johnson and Takeda. Nicolaas P.A. Zuithoff has nothing to disclose. Lisa P. van der Rijst has nothing to disclose. Celeste M. Boesjes has nothing to disclose. Judith L. Thijs is a speaker for Sanofi Genzyme and LEO Pharma. Joke H. de Boer received research funding from Abbvie; this is outside the submitted work. Marjolein S. de Bruin‐Weller is a consultant, advisory board member and/or speaker for AbbVie, Almirall, Aslan, Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron and Sanofi‐Genzyme. ",
year = "2022",
month = jun,
doi = "10.1111/cea.14127",
language = "English",
volume = "52",
pages = "801--805",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "6",
}